Events
Conferences we attend
Upcoming Conferences
Virtual or in person, we participate in many conferences as speakers, exhibitors or attendees.
We regularly attend conferences organised by the American Chemical Society (ACS), the Royal Society of Chemistry, The International Society for the Study of Xenobiotics (ISSX), the Drug Metabolism Discussion Group (DMDG) the Society of Chemical Industry (SCI), the Pharmaceutical and Bioscience Society (PBSS) and The Boston Society.
Let us know if you’d like to connect at any of the meetings we’re attending this year.
Liam Evans will be presenting a poster at Drug Discovery Chemistry 2023 being held in San Diego, USA from 10-13 April 2023.
Frank Scheffler will be attending the ACS Spring meeting being held in Indianapolis from 26-30 March 2023.
Hypha are pleased to be sponsoring the ISSX workshop 2023 on “Small Molecule Metabolites in Drug Discovery and Development” running 1-3 March 2023.
Samuel Coe will be attending the joint SMR/RSC meeting on “Recent Trends in Medicinal Chemistry and Enabling Technologies” on 8th December 2022 in London.
Our partner BioBridge will be representing Hypha at the 37th annual meeting of The Japanese Society for the Study of Xenobiotics (JSSX) being held 7-10 November 2022.
Frank Scheffler will be attending KSNS The multiverse of new therapeutics via emerging biotechnologies in South Korea from 5-6 October 2022.
Samuel Coe will be exhibiting at the DMDG 2022 joint meeting being held 3-5 October 2022 in Amsterdam.
Samuel Coe will be attending the Oxford BioForward Event on 27th September 2022. Let us know if you’d like to meet with Sam.
Sam will be presenting a poster at the RSC Chemical Biology meets Drug Discovery meeting being held 12-13 September 2022 on “PolyCYPs: Biocatalytic Tools for the Optimisation of Drug Leads”
Stay up to date with the latest news from Hypha Discovery
Sign up for our quarterly newsletters and monthly "Metabolite Tales" blog
Ready to begin? Our scientists are available to talk through your requirements
Hypha Discovery is a UK-based CRO supporting pharmaceutical and agrochemical companies worldwide through the production of metabolites and new derivatives of drugs and agrochemicals in discovery and development.